Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).
Biocon Biologics’ strong R&D and manufacturing capabilities have enabled the company to offer affordable biologics such as bTrastuzumab and bPegfilgrastim to cancer patients in developed markets like the European Union and the United States. Biocon Biologics will initially supply bTrastuzumab and bPegfilgrastim and will expand the arrangement to include other biosimilars.
Kiran Mazumdar Shaw
“The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through cost-effective alternatives to expensive reference biologics.”